Lund, Sweden, 7 October, 2025, Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that Renée Aguiar-Lucander, CEO, will be participating at Optimum’s 17th Annual Healthcare Investor Conference on Thursday 9 October, 2025 in London, and at Nordic Life Science Days 2025 (NLSDays) in Gothenburg on Tuesday 14 October, 2025.

At Optimum’s Healthcare Investor Conference, Aguiar-Lucander will participate in a panel discussing exit strategies in the pharmaceutical industry from 11:05 to 11:50 BST.

At NLSDays, Hansa’s CEO will moderate a supersession titled “Financing the Future of Life Science – Strategies, Trends, and Opportunities” between 14:00 and 14:45 CEST to explore the current and future state of financing in the sector alongside other leading investors, financial strategists, and venture capitalists.

Event: Optimum 17^th Annual Healthcare Investor Conference, Exit Strategies Panel

Date and Time: Thursday 9 October, 11:05-11:50 BST

Chair: Nick Bastin, Managing Partner, Optimum

Panel:

• Renée Aguiar-Lucander, CEO, Hansa Biopharma
• Hakan Goker, Managing Director, M Ventures
• Premal Pajwani, Founder and CEO, PRP Advisory
• Peter van de Sande, CEO, Synaffix

For more information: https://www.optimumcomms.com/irconference2025/

Event: NLSDays, Financing the Future of Life Science – Strategies, Trends, and Opportunities

Date, Time, and Place: Tuesday 14 October, 14:00-14:45 CEST, Expo Stage

Moderator: Renée Aguiar-Lucander, CEO, Hansa Biopharma

Speakers:

• Mette Kirtine Agger, Advisor, Board Member, CEO, Avante Biocapital
• Sonia Benhamida, Managing Director, BlackRock
• Kristofer Klerfalk, Entrepreneur, Managing Partner, Life Science Invest
• Peter Horn Møller, Founding Partner, Marigold Investment Management

For more information: https://nlsdays.com/program/2025-financing-the-future-of-life-science/

--- ENDS ---

Contacts for more information:

Evan Ballantyne, Chief Financial Officer
IR@hansabiopharma.com

Kerstin Falck, VP Global Corporate Affairs
[email protected]

Notes to editors

About Hansa Biopharma

Hansa Biopharma AB is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions. The company has a rich and expanding research and development program based on its proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in autoimmune diseases, gene therapy and transplantation. The company’s portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients and HNSA-5487, a next-generation IgG cleaving molecule with redosing potential. Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at www.hansabiopharma.com and follow us on LinkedIn.

©2025 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All rights reserved.